Twist Bioscience Co. (NASDAQ:TWST) Director Sells $250,000.00 in Stock

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) Director Robert Chess sold 5,000 shares of Twist Bioscience stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $50.00, for a total value of $250,000.00. Following the transaction, the director now directly owns 16,641 shares of the company's stock, valued at $832,050. The trade was a 23.10 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Robert Chess also recently made the following trade(s):

• On Thursday, December 5th, Robert Chess sold 3,504 shares of Twist Bioscience stock. The shares were sold at an average price of $51.85, for a total value of $181,682.40.
• On Monday, November 11th, Robert Chess sold 3,600 shares of Twist Bioscience stock. The shares were sold at an average price of $47.26, for a total value of $170,136.00.

Twist Bioscience Trading Down 3.4 %

TWST stock traded down $1.52 during trading on Friday, reaching $43.60. The stock had a trading volume of 807,199 shares, compared to its average volume of 683,350. Twist Bioscience Co. has a 52 week low of $27.41 and a 52 week high of $60.90. The stock's 50 day moving average is $46.35 and its two-hundred day moving average is $46.46. The firm has a market cap of $2.59 billion, a PE ratio of -12.11 and a beta of 1.85.

Analysts Set New Price Targets

TWST has been the subject of a number of recent research reports. Scotiabank boosted their target price on Twist Bioscience from $50.00 to $54.00 and gave the stock a "sector outperform" rating in a research report on Tuesday, November 19th. Barclays dropped their target price on Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating for the company in a research report on Tuesday, November 19th. TD Cowen restated a "buy" rating and issued a $58.00 target price on shares of Twist Bioscience in a research report on Tuesday, November 26th. Robert W. Baird boosted their price objective on Twist Bioscience from $46.00 to $48.00 and gave the company an "outperform" rating in a research report on Tuesday, November 19th. Finally, Wolfe Research started coverage on Twist Bioscience in a research report on Friday, December 13th. They issued an "outperform" rating and a $60.00 price objective for the company. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $51.90.

Institutional Trading of Twist Bioscience

A number of hedge funds and other institutional investors have recently bought and sold shares of TWST. Massachusetts Financial Services Co. MA grew its position in shares of Twist Bioscience by 215.9% during the third quarter. Massachusetts Financial Services Co. MA now owns 29,314 shares of the company's stock worth $1,324,000 after purchasing an additional 20,035 shares in the last quarter. Barclays PLC grew its position in shares of Twist Bioscience by 214.8% during the third quarter. Barclays PLC now owns 153,039 shares of the company's stock worth $6,913,000 after purchasing an additional 104,420 shares in the last quarter. FMR LLC grew its position in shares of Twist Bioscience by 6.0% during the third quarter. FMR LLC now owns 218,561 shares of the company's stock worth $9,875,000 after purchasing an additional 12,327 shares in the last quarter. BNP Paribas Financial Markets grew its position in shares of Twist Bioscience by 128.1% during the third quarter. BNP Paribas Financial Markets now owns 38,032 shares of the company's stock worth $1,718,000 after purchasing an additional 21,357 shares in the last quarter. Finally, Principal Financial Group Inc. grew its holdings in Twist Bioscience by 67.5% during the 3rd quarter. Principal Financial Group Inc. now owns 205,864 shares of the company's stock valued at $9,301,000 after buying an additional 82,953 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.